WO2000013510A1 - Compositions antibacteriennes - Google Patents
Compositions antibacteriennes Download PDFInfo
- Publication number
- WO2000013510A1 WO2000013510A1 PCT/JP1999/004727 JP9904727W WO0013510A1 WO 2000013510 A1 WO2000013510 A1 WO 2000013510A1 JP 9904727 W JP9904727 W JP 9904727W WO 0013510 A1 WO0013510 A1 WO 0013510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- antibacterial composition
- aminocarboxylic acid
- represented
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/22—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients stabilising the active ingredients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
Definitions
- the present invention relates to antimicrobial compositions. More specifically, the present invention relates to an antibacterial composition containing an isothiazolone compound, capable of suppressing the decomposition of the isothiazolone compound, and reducing the skin irritation of the isothiazolone compound.
- Isothiazolone compounds typified by 5-chloro-2-methyl-4-isothiazolin-3-one have excellent antibacterial activity, and are used in various applications such as cooling water systems, paper pulp, paints, adhesives, cutting oils, and human waste treatment. It is widely used as a slime control agent, antibacterial agent, antialgal agent, and antifungal agent. Since isothiazolone compounds are extremely unstable compounds, it is necessary to study for improving product stability in order to effectively use chemicals containing these compounds. Various efforts have been made.
- Japanese Patent Publication No. 54-239688 discloses a biocidally active compound which is useful for controlling various biological organisms, especially microorganisms, and furthermore, contains ordinary additives and dirt.
- Dyestuffs-Metal salt complexes such as calcium chloride and zinc chloride, which are isothiazolone compounds, have been proposed as a complex that resists decomposition under extreme conditions and has particularly excellent thermal stability.
- U.S. Patent No. 3,870,795 discloses that a metal nitrate such as calcium nitrate or magnesium nitrate or a metal nitrite such as sodium nitrite or calcium nitrite is added to a solution of an isothiazolone compound. It has been reported that by doing so, the decomposition of the isothiazolone compound can be suppressed and stabilized.
- Japanese Unexamined Patent Publications Nos. 61-56 61-174 and 61-212 125 76 disclose isothiazolone compounds such as 5-chloro-2-methyl-14-isothiazolin-13-one.
- a solution of propylene glycol, 1,5-pentanediol, benzyl alcohol, etc., and a metal salt such as copper chloride, sodium chloride, magnesium chloride, copper nitrate, etc., and a stabilizing solution of isothiazones are proposed. ing.
- Japanese Patent Application Laid-Open No. 5-124917 proposes a method for protecting against decomposition using a combination of isothiazolone and a sulfur-containing compound such as L-cystine.
- L-cystine has a problem that its solubility in water and hydrophilic organic solvents is low, and it is difficult to mix it. For this reason, there has been a demand for an antibacterial composition having excellent stability and capable of suppressing the decomposition of the isothiazolone compound.
- Japanese Patent Application Laid-Open No. 5-246807 discloses a composition of a polycationic compound such as polylysine and isothiazolone, but polylysine has an effect of suppressing decomposition of an isothiazolone compound. Is known to have no.
- An object of the present invention is to provide an antibacterial composition containing an isothiazolone compound, capable of suppressing the decomposition of the isothiazolone compound, and reducing the skin irritation of the isothiazolone compound. Disclosure of the invention
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, a specific amino carboxylic acid and its derivative have the effect of stabilizing the isothiazolone compound and reducing the skin irritation of the isothiazolone compound. This led to the completion of the present invention based on this finding.
- An antibacterial composition comprising an isothiazolone compound represented by the general formula [1] or [2] and an aminocarboxylic acid represented by the general formula [3] or a derivative thereof.
- R 1 is hydrogen, an alkyl group, an alkenyl group, an alkynyl group, or an aralkyl group.
- X and Y are hydrogen, halogen, or carbon, together with carbons at positions 4 and 5 of the isothiazolone compound.
- M is a cation of an alkali metal, an alkaline earth metal, a heavy metal or an amine, and Z is a compound with a cation M having sufficient solubility to form a complex compound.
- A is an anion to be formed, a is 1 or 2, and n is an integer such that the anion Z satisfies the valency of the cation M.
- R 2 is hydrogen or an unsubstituted or carboxyl-substituted alkyl group having 1 to 5 carbon atoms
- R 3 is a linear or branched alkylene group having 1 to 5 carbon atoms
- R 4 is hydrogen or an unsubstituted or substituted carbon atom having a carbon number of 1 to 5 substituted with a carboxyl group, a hydroxyl group, a hydroxyl group, a phenyl group, a hydroxyphenyl group, a ureido group, a methylthio group or a 4-imidazolyl group.
- R 2 and R 4 together with N— (R 3 ) b—C form an unsubstituted, hydroxyl-substituted or oxo-substituted heterocyclic group, wherein b is 0 or 1. is there. ) ,
- the aminocarboxylic acid derivative represented by the general formula [3] is a metal salt of the aminocarboxylic acid represented by the general formula [3], or one or two kinds represented by the general formula [3] Less than A compound in which the above aminocarbonic acid is bonded by a peptide bond or a metal salt thereof, a compound in which the aminocarboxylic acid represented by the general formula [3] and another aminocarboxylic acid are bonded by a peptide bond, or a metal salt thereof, a general formula
- the antibacterial composition according to item (1) which is an N-acetylated product of an aminocarboxylic acid represented by [3] or a metal salt thereof, or an amide of an aminocarboxylic acid represented by general formula [3]:
- the content of the aminocarboxylic acid represented by the general formula [3] or a derivative thereof is 0.1 to 50 times the content of the isothiazolone compound represented by the general formula [1] or [2].
- the antibacterial composition according to (1) is 0.1 to 50 times the content of the isothiazolone compound represented by the general formula [1] or [2].
- the antibacterial composition of the present invention contains an isothiazolone compound represented by the general formula [1] or [2] and an aminocarboxylic acid represented by the general formula [3] or a derivative thereof.
- R 1 is hydrogen, an alkyl group, an alkenyl group, an alkynyl group or an aralkyl group.
- X and Y are hydrogen, halogen, or those forming a benzene ring together with the carbons at the 4th and 5th positions of the isothiazolone compound.
- M is a cation of an alkali metal, an alkaline earth metal, a heavy metal or an amine
- Z is an anion that forms a compound with the cation M having sufficient solubility to form a complex compound.
- a is 1 or 2
- n is an integer in which the cation Z satisfies the valence of the cation M.
- R 2 is hydrogen or an unsubstituted or substituted by a carboxyl group alkyl group having 1 to 5 carbon atoms
- R 3 is a linear or branched carbon atom having 1 carbon atom.
- R 4 is hydrogen or an unsubstituted or carboxyl group (one COOH), a carbamoyl group (one CONH 2 ), a hydroxyl group (one OH), a phenyl group (one C 6 H 5 ), Hydroxyphenyl group (one C 6 H 4 OH), peridode group (one NHCONHz), methylthio group (one SCH 3 ) or 4-imidazolyl group
- Examples of the isothiazolone compound represented by the general formula [1] include 2-methyl-4-1-isothiazoline-3-one, 2-ethyl-4-isothiazoline-3-one, 2-octyl-4-isothiazoline-13-one, 5-chloro-2-methyl-1-isothiazoline-3-one, 5-chloro-1-octyl-4-isothiazoline-3_one, 4,5-dichloro-1--2-methyl-4-isothiazoline-3-one, 4 , 5-dichloro-1-octyl-4-isothiazolin-3-one; 1,2-benzoisothiazolin-3-one; and the like.
- Examples of the isothiazolone compound represented by the general formula [2] include, for example, a complex compound of the above-mentioned isothiazolone compound represented by the general formula [1] with magnesium chloride, magnesium nitrate, copper chloride, copper nitrate, calcium chloride, and the like. Can be mentioned.
- aminocarboxylic acid represented by the general formula [3] examples include glycine, alanine, ⁇ -ryanine, nocrine, leucine, isoleucine, serine, trenin, aspartic acid, glutamic acid, asparagine, and glutamine. , Sarcosine, cytonorellin, methionine, ⁇ -aminobutyric acid, 3-aminobutyric acid, ⁇ -aminobutyric acid, ⁇ -aminocaproic acid, phenylalanine, tyrosine, histidine, proline, 4-hydroxyproline, 2-pyrrolidone-15-carboxylic acid And imino diacetic acid.
- Such compounds include, for example, glycylglycine, glycylglycylglycine, glycylglycylglycylglycine, glycylalanine, glycylasparagine, glycylleucine, glycylisoloisin, glycylphenylalanine, glycylproline, glycylsarcosine, Glycylserine, glycylthreonine, glycylvaline, glycylglutamine, aranylalanine, aranylasparagine, aranylglutamine,
- Examples of ⁇ -acetylated products of the aminocarboxylic acid represented by the general formula [3] include ⁇ -acetylglycine, ⁇ -acetylalanine, ⁇ -acetyl-L-asparaginic acid, ⁇ -acetyl-L-glutamic acid, and ⁇ -acetylamine. — Acetyltyrosine and the like.
- Examples of the amide of the aminocarboxylic acid represented by the general formula [3] include glycine amide.
- Examples of the metal salt of the compound represented by the general formula [3] or a derivative thereof include a lithium salt, a sodium salt, a potassium salt, a calcium salt, and a magnesium salt.
- the aminocarboxylic acid represented by the general formula [3] may have a DL-form, an L-form, and a D-form, and the composition of the present invention includes a DL-form, an L-form, and a D-form. —You can use any body.
- glycine and sodium glutamate can be particularly preferably used as the aminocarboxylic acid represented by the general formula [3] and its derivative.
- Daricin and sodium glutamate have a high dissolution rate, so that an antimicrobial composition can be prepared quickly. Since the molecular weight is small, the general formula [1] or the general formula
- the concentration of the isothiazolone compound represented by the general formula [1] or [2] is not particularly limited, but is preferably 0.1 to 10% by weight, and 0.5 to 8% by weight. % Is more preferable. If the concentration of the isothiazolone compound represented by the general formula [1] or the general formula [2] is less than 0.1% by weight, the capacity of the antibacterial composition as a product increases, and the economical efficiency in transportation, storage, and the like increases. It may be damaged. If the concentration of the isothiazolone compound represented by the general formula [1] or [2] exceeds 10% by weight, the stability of the antibacterial composition may be impaired.
- the concentration of the aminocarboxylic acid represented by the general formula [3] or the derivative thereof is not particularly limited, but the concentration of the isothiazolone compound represented by the general formula [1] or the general formula [2] is The molar ratio is preferably 0.1 to 50 times, more preferably 1 to 10 times. If the concentration of the aminocarboxylic acid represented by the general formula [3] or a derivative thereof is less than 0.1 mol times the isothiazolone compound, the stability of the antibacterial composition is impaired, and the isothiazolone compound is easily decomposed. Skin irritation may appear strongly.
- Aminocarboxylic acid represented by general formula [3] the concentration of the derivative thereof is usually sufficient to be 50 mol times or less of the isothiazolone compound, and more than 50 mol times of the isothiazolone compound is mixed with the aminocarboxylic acid represented by the general formula [3] or the derivative thereof.
- the effect of reducing the stability and skin irritation of the antibacterial composition is not further improved.
- the amino carboxylic acid derivative represented by the general formula [3] is a polyamino acid
- the concentration in the antibacterial composition is preferably 0.1 to 20% by weight.
- the solvent used in the composition of the present invention is a solvent in which the isothiazolone compound represented by the general formula [1] or [2] and the aminocarboxylic acid represented by the general formula [3] or a derivative thereof are dissolved.
- the target system is often an aqueous system, it is preferably water or a hydrophilic organic solvent.
- the hydrophilic organic solvent include amides such as dimethylformamide, glycols such as ethylene glycol, propylene glycol, diethylene glycol and dipropylene glycol, methyl sorb, phenyl sorb, and the like.
- Glycol esters such as diethylene glycol monomethyl ether and dipropylene dalicol monomethyl ether, alcohols having 8 or less carbon atoms, methyl acetate, ethyl acetate, 3-methoxybutyl acetate, 2-ethoxybutyl acetate, 2-ethoxy Esters such as quinpropyl acetate and propylene carbonate can be exemplified.
- PH of the antimicrobial composition of the present invention is preferably set to 7 or less, in particular a P H 2 to 5, not preferred in terms of enhancing the stability of the Isochiazoron compound.
- the antibacterial composition of the present invention may further contain, if necessary, a corrosion inhibitor, a scale inhibitor, an antibacterial agent other than the isothiazolone compound, an antifoaming agent, a surfactant, an antialgal agent, and the like.
- Corrosion inhibitors include, for example, tolyltriazole, benzotriazole, methylbenzotriazole, molybdic acid, tungstic acid, gay acid, nitrous acid, 2-phosphonobutane-1,2,4-tricarboxylic acid, hydroxyethylidene diacid Phosphonic acid, hexametaphosphoric acid, tripolyphosphoric acid, orthophosphoric acid and their salts, zinc chloride, zinc chloride hydrochloride, zinc sulfate, zinc ligninsulfonate, hydrazine, etc. Can be mentioned.
- the scale inhibitor examples include polyacrylic acid, a copolymer of acrylic acid Z 2 -hydroxymethyl methacrylate, and a copolymer of acrylnoic acid Z 2 -hydroxyethyl methacrylate nomethylacrylate Copolymer of acrylic acid, Z-arylglycidyl ether, copolymer of acrylic acid 2-hydroxy-3-aryloxy-1-propanesulfonic acid, copolymer of acrylic acid / isoprenesulfonic acid, acrylic acid Z-vinyl sulfonic acid copolymer, atarilic acid Z-aryl sulfonic acid copolymer, polymaleic acid, maleic acid or maleic anhydride Z isobutylene copolymer, maleic acid or maleic anhydride Z styrene sulfonic acid copolymer Copolymer of maleic acid or maleic anhydride Z-acrylic acid, maleic acid or maleic anhydride Z2-acrylic acid DO copolymer of 2-methylpropa
- Antibacterial agents include, for example, halogenated aliphatic nitrated compounds such as 2-promo-2-nitro-1,3-propanediol, 2,2-dibromo-12-nitroethanol and their esters, dibromonitrile Methyl propionamide, alkylenebisthiocyanates such as methylene bisthiocyanate, 1,4-bisbromoacetoxy-1-butene, hexabromodimethylsulfone, 5-chloro-2,4,6-trifluoroisophthalo Nitrinole, tetrachloro-mouth isophthalonitrile, and other isocyanate-based nitronitrile compounds, dimethyldithi-substituted rubamate, 4,5-dichloro-1,2-dithiol-3-one, 3,3,4,4, -tetrachloro Tetrahydrothiophenyl-1,1-dioxide, triiodoallyl alcohol, bromonitrostyrene,
- Examples of the defoaming agent include a silicone-based or non-silicon-based defoaming agent, a surfactant Examples thereof include anionic, cationic, nonionic and amphoteric surfactants, and examples of the anti-algal agent include triazine compounds such as amethrin.
- composition of the present invention 0.1 to 10% by weight of an isothiazolone compound represented by the general formula [1] or [2], an aminocarboxylic acid represented by the general formula [3] or a derivative thereof 0.1 to 20% by weight, corrosion inhibitor 0 to 50% by weight, scale inhibitor 0 to 50% by weight, antibacterial agent 0 to 30% by weight, defoamer 0 to 10% by weight, surface activity
- an antimicrobial composition containing 0 to 10% by weight of an agent, 0 to 10% by weight of an antialgal agent, and 30 to 99% by weight of water or a hydrophilic organic solvent can be exemplified.
- the antimicrobial composition of the present invention can be used by appropriately selecting the concentration depending on the object and purpose.
- concentration of the isothiazolone compound is 0. 1 ⁇ 2 5 gZm 3, synthetic resin Emarujiyon, starch paste, starch slurry, paint
- concentration of the isothiazolone compound is preferably 1 to 50,000 g / m 3 .
- the antibacterial composition of the present invention contains an isothiazolone compound and an aminocarboxylic acid or a derivative thereof, has excellent stability over time and heat stability, and does not cause decomposition of the isothiazolone compound even when stored for a long period of time.
- the compound exhibits excellent antibacterial effects based on the compound, and the skin irritation of the isotizazolone compound is reduced, so that it can be handled easily.
- Ethylenedaricol solution containing 11% by weight of 5-chloro-2-methyl-4-1-isothiazolin-3-one and 1% by weight of 2-methyl-4-isothiazolin-3-one [ZONEN-F, Takakawa Synthetic Chemical Co., Ltd. 5.0 parts by weight, 0.62 parts by weight of glycine and 94.38 parts by weight of water were mixed and uniformly dissolved to prepare an antibacterial composition.
- This antimicrobial composition contains glycine at a molar ratio of 2 moles to the total number of moles of 5-chloro-2-methyl-4-isothiazolin-13-one and 2-methyl-14-isothiazolin-13-one. .
- aminocarboxylic acids represented by the general formula [3] or derivatives thereof include alanine, ⁇ -ryanine, DL-serine, DL-threonine, DL-asparagine, L-glutamine, sarcosine, and DL- /?
- the obtained 26 kinds of antibacterial compositions were left at room temperature for one month, but all the antibacterial compositions remained in a transparent liquid state, and no precipitate was observed.
- Table 1 shows the results of Example 1 and Comparative Example 1.
- Example 2 As shown in Table 1, it contains 5-methyl-1--2-methyl-3-isothiazolin-13-one and 2-methyl-4-isothiazolin-13-one, and is an aminoaminocarbon represented by the general formula [3]
- Antibacterial composition of Comparative Example 1 containing no acid or derivative thereof Precipitates when left at room temperature for one month, but the antimicrobial composition of Example 1 containing the aminocarboxylic acid represented by the general formula [3] or its derivative is left at room temperature for one month. No change in appearance was observed, indicating that the stability with time was excellent.
- Example 2 Example 2
- the antibacterial composition prepared in Comparative Example 1 was left in a thermostat kept at 60 ° C. for 48 hours, and then the content of 5-chloro-1,2-methyl-14-isothiazolin-13-one was determined. It was measured by high performance liquid chromatography. In the chromatogram, there was no peak of 5-chloro-2-methyl-14-isothiazolin-13-one, and 5-chloro-1-methyl-4-isothiazolin-13-one was completely decomposed.
- Ethylene glycol solution containing 11% by weight of 5-methyl-2-1-methyl-4-1-isothiazolin-3-one and 1% by weight of 2-methyl-1-isothiazolin-3-one [ZONEN-F, Ichikawa Synthetic Chemistry 5.0 parts by weight, 2.0 parts by weight of polylysine and 93.0 parts by weight of water were mixed and uniformly dissolved to prepare an antibacterial composition. After leaving this antibacterial composition for 48 hours in a thermostat kept at 60 ° C, the content of 5-chloro-1-methyl-14-Tsothiazoline-13-one was determined by high-performance liquid chromatography. Measured by one. The chromatogram did not show the peak of 5-chloro-1-methyl-4-isothiazolin-3-one, and the 5-chloro-1-methyl-14-isothiazolin-3-one was completely decomposed.
- Table 2 shows the results of Example 2 and Comparative Examples 2 and 3.
- glycylglycine, glycylglycylglycine, glycylglycylglycine, glycylglycylglycylglycine, glycylglycylglycine, glycyl-L-glutamine, L-aralanyl which is a compound in which aminoamino acids represented by the general formula [3] are bound by a peptide bond
- 5-chloro-2-methyl-4-isothiazolin-13-one is not decomposed at all and maintains a residual ratio of 100%.
- Comparative Example 4 5-Aqueous solution containing 2-methyl-1-isothiazolin-3-one 12-methyl-4-isothiazolin-3-one 3% by weight, magnesium chloride and magnesium nitrate [KATHON-WT, 5.0 parts by weight and 95.0 parts by weight of water and uniformly dissolve to prepare an antibacterial composition.
- the antimicrobial composition is 60. After standing at C for 48 hours, the content of 5-chloro-2-methyl-14-isothiazolin-13-one was measured by high performance liquid chromatography. The residual ratio of 5-chloro-2-methyl-14-isothiazolin-13-one was 51%.
- Table 3 shows the results of Example 3 and Comparative Example 4.
- glycylglycine, glycylglycylglycine, glycylglycylglycine, and glycylglycylglycine are compounds in which the aminocarboxylic acid represented by the general formula [3] is bonded through peptide bonds.
- L-Glutamine, L-Garalanil The antimicrobial composition of Example 3 containing L-glutamine was left at 60 ° C. for 48 hours to obtain 5-methyl-1-2-methyl-41-isothiazoline-13. -ON does not decompose at all and maintains a residual rate of 100%.
- Comparative Example 4 which does not contain the aminocarboxylic acid represented by the general formula [3] or the derivative thereof has low thermal stability, and when left at 60 ° C for 48 hours, 5-chloro- About half of 2-methyl-1-isothiazolin-3-one is degraded.
- Example 4 Ethylene glycol solution containing 11% by weight of 5-chloro-2-methyl-4 ⁇ sothiazolin-3-one and 1% by weight of 2-methyl-4-isothiazolin-3-one [ZONEN-F, manufactured by Takakawa Synthetic Chemical Co., Ltd.] 5.0 parts by weight, 1.09 parts by weight of glycylglycine and 93.91 parts by weight of water were mixed and uniformly dissolved to prepare an antibacterial composition.
- This antibacterial composition contains glycylglycine in a molar ratio of 2 times the total number of moles of 5-chloro-2-methyl-14-isothiazolin-13-one and 2-methyl-4-isothiazolin-13-one. Ba ciluss ub tillus was used to examine the growth inhibitory effect of this antibacterial composition.
- Bacillus ub tillus is inoculated in a liquid medium of pH 7 containing 1 g / litre of peptone and 1 g of yeast extract at a concentration of 10 6 Bacillus stubillus at a concentration of 2 Omg with the above antibacterial composition. / Liter, 6 Omg little and 10 Omg little, and cultured with shaking at 30 ° C for 24 hours.
- concentration of the antibacterial composition was 2 Omg / liter, no growth inhibitory effect was observed, but when the concentration was 60 mg / liter and 10 Omg / liter, the growth inhibitory effect was observed.
- the concentration of the antibacterial composition was 20 nig liters, no growth inhibitory effect was observed, but when the concentrations were 60 rag / liter and 100 mgZ liter, growth inhibitory effects were observed.
- the antibacterial effect of this antibacterial composition on Bacillus subtilus was examined in the same manner as in Example 4. When the concentration of the antibacterial composition was 2 OmgZ liter, no growth inhibitory effect was observed, but when the concentrations were 6 OmgZ liter and 10 Omg / liter, the growth inhibitory effect was observed.
- Ethylene glycol solution containing 11% by weight of monoisothiazolin-3-one and 1% by weight of 2-methyl-1-isothiazolin-3-one [ZONEN-F, manufactured by Takakawa Synthetic Chemical Co., Ltd.] 5.0 parts by weight, 2-fold moles of the amino carboxylic acid or its derivative with respect to the total number of moles of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one, and the total amount of 10.0 weight Water was mixed and uniformly dissolved to prepare four kinds of antibacterial compositions.
- This antibacterial composition was subjected to the skin irritation test described above.
- Comparative Example 6 None 4.00 4.00 4.00 4.00 7.25 an 1 7.3 3 7.00 0 7.3 3 7.3 3 As can be seen in Table 5, comparing Example 5 with Comparative Example 6 having the same composition except for the presence or absence of aminocarboxylic acid or its derivative, it was found that glycine, sodium L-glutamate, iminoniacetic acid or glycylglycine was contained.
- the antibacterial composition of Example 5 had a smaller skin primary irritation index than the antibacterial composition of Comparative Example 6 containing no aminocarboxylic acid or a derivative thereof, and was formulated with an aminocarboxylic acid or a derivative thereof. It can be seen that skin irritation of the contained antimicrobial composition is reduced. Industrial applicability
- the antibacterial composition of the present invention contains an isothiazolone compound and an aminocarboxylic acid or a derivative thereof, has excellent stability over time and heat stability, and does not cause decomposition of the isothiazolone compound even when stored for a long period of time. It exhibits an excellent antibacterial effect based on the compound, and reduces the skin irritation of the isothiazolone compound, so that it can be handled easily.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99940595A EP1110455B1 (en) | 1998-09-03 | 1999-08-31 | Antibacterial compositions |
DE69908954T DE69908954T2 (de) | 1998-09-03 | 1999-08-31 | Antibakterielle zusammensetzungen |
AT99940595T ATE242969T1 (de) | 1998-09-03 | 1999-08-31 | Antibakterielle zusammensetzungen |
US09/786,291 US6429220B1 (en) | 1998-09-03 | 1999-08-31 | Antibacterial compositions |
BR9913385-7A BR9913385A (pt) | 1998-09-03 | 1999-08-31 | Composição antimicrobiana |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24973698 | 1998-09-03 | ||
JP10/249736 | 1998-09-03 | ||
JP11/230876 | 1999-08-17 | ||
JP23087699A JP3722268B2 (ja) | 1998-09-03 | 1999-08-17 | 抗菌性組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000013510A1 true WO2000013510A1 (fr) | 2000-03-16 |
Family
ID=26529588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/004727 WO2000013510A1 (fr) | 1998-09-03 | 1999-08-31 | Compositions antibacteriennes |
Country Status (12)
Country | Link |
---|---|
US (1) | US6429220B1 (ja) |
EP (1) | EP1110455B1 (ja) |
JP (1) | JP3722268B2 (ja) |
KR (1) | KR100413845B1 (ja) |
CN (1) | CN1163137C (ja) |
AT (1) | ATE242969T1 (ja) |
BR (1) | BR9913385A (ja) |
DE (1) | DE69908954T2 (ja) |
ES (1) | ES2203167T3 (ja) |
ID (1) | ID28716A (ja) |
TW (1) | TW486362B (ja) |
WO (1) | WO2000013510A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4934896B2 (ja) * | 2000-12-22 | 2012-05-23 | 三菱瓦斯化学株式会社 | 多機能型水処理剤 |
JP5456234B2 (ja) * | 2003-06-30 | 2014-03-26 | アルザ・コーポレーシヨン | 非揮発性の対イオンを含有する被覆された微小突起のための製剤 |
US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
US20050136118A1 (en) * | 2003-12-19 | 2005-06-23 | Wu Su-Syin S. | Distribution and preparation of germicidal compositions |
US7476767B2 (en) * | 2004-01-30 | 2009-01-13 | Ethicon, Inc. | Alpha-hydroxy sulfonate aldehydes, germicidal compositions containing the alpha-hydroxy sulfonate aldehydes, or mixtures of alpha-hydroxy sulfonate aldehydes and phthalaldehydes, and methods of using the compounds or compositions for disinfection or sterilization |
US20050171216A1 (en) * | 2004-01-30 | 2005-08-04 | Zhu Peter C. | Germicidal compositions containing phthalaldehyde mixtures and methods of using such compositions for disinfection or sterilization |
US7390837B2 (en) * | 2004-01-30 | 2008-06-24 | Ethicon, Inc. | Germicidal compositions containing phenylmalonaldehyde-type compounds, or mixtures of phenylmalonaldehyde-type compounds and phthalaldehydes, and methods of using such compositions for disinfection or sterilization |
US7468384B2 (en) * | 2004-11-16 | 2008-12-23 | Rohm And Haas Company | Microbicidal composition |
US8138156B2 (en) * | 2006-10-18 | 2012-03-20 | Bausch & Lomb Incorporated | Ophthalmic compositions containing diglycine |
JP5390384B2 (ja) * | 2007-07-19 | 2014-01-15 | 日本曹達株式会社 | イソチアゾロン化合物の亜鉛塩、イソチアゾロン化合物の低刺激化方法、イソチアゾロン化合物の亜鉛塩を用いる抗菌・防カビ方法、および抗菌・防カビ組成物 |
US8629099B2 (en) * | 2008-03-25 | 2014-01-14 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising a dipeptide |
EP2149364A1 (en) * | 2008-07-24 | 2010-02-03 | Rohm and Haas Company | Method for reducing odor in personal care products |
WO2011145083A2 (en) | 2010-05-20 | 2011-11-24 | Ecolab Usa Inc. | Rheology modified low foaming liquid antimicrobial compositions and methods of use thereof |
US8664180B2 (en) | 2012-02-06 | 2014-03-04 | Bausch & Lomb Incorporated | Ophthalmic compositions containing diglycine |
US8324171B1 (en) | 2012-02-06 | 2012-12-04 | Bausch & Lomb Incorporated | Ophthalmic compositions containing diglycine |
WO2020246452A1 (ja) * | 2019-06-03 | 2020-12-10 | 株式会社ケミクレア | 安定な殺微生物剤組成物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5287230A (en) * | 1976-01-12 | 1977-07-20 | Kao Corp | Antimicrobial composition |
JPS62252708A (ja) * | 1986-03-04 | 1987-11-04 | サツトン・ラボラトリ−ズ・インコ−ポレ−テツド | 微生物増殖抑制組成物 |
JPH03178969A (ja) * | 1989-10-24 | 1991-08-02 | Rohm & Haas Co | 安定化した金属塩/3―イソチアゾロンの組成物 |
JPH09263504A (ja) * | 1995-12-19 | 1997-10-07 | Takeda Chem Ind Ltd | イソチアゾロン系化合物含有組成物及びイソチアゾロン系化合物の安定化法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3415655A (en) * | 1965-10-19 | 1968-12-10 | Ajinomoto Kk | Milk product containing free amino acids and method of preparing the same |
US4150026A (en) | 1971-05-12 | 1979-04-17 | Rohm And Haas Company | Metal salt complexes of 3-isothiazolones |
US3870795A (en) | 1973-02-28 | 1975-03-11 | Rohm & Haas | Stabilization of solutions of 3-isothiazolones employing certain metal nitrates and nitrites |
JPS5843916B2 (ja) | 1977-07-25 | 1983-09-29 | 松下電器産業株式会社 | 電気回路の接続方法 |
IL75598A (en) | 1984-06-27 | 1990-07-12 | Rohm & Haas | Stabilized aqueous solutions of 5-chloro-3-isothiazolones,their preparation and their use |
GB8416314D0 (en) | 1984-06-27 | 1984-08-01 | Rohm & Haas | Stabilization of aqueous solutions |
US4824957A (en) | 1985-03-08 | 1989-04-25 | Rohm And Haas Commpany | Stabilization of non-aqueous solutions of 3-isothiazolones |
DK166644B1 (da) * | 1985-03-08 | 1993-06-28 | Rohm & Haas | Fremgangsmaade til fremstilling af en stabil 5-chlor-4-isothiazolin-3-onoploesning og anvendelse af denne oploesning som biocid eller konserveringsmiddel |
US4980176A (en) | 1986-03-04 | 1990-12-25 | Sutton Laboratories, Inc. | Preservative compositions and uses thereof |
DE3911808A1 (de) | 1989-04-11 | 1990-10-18 | Riedel De Haen Ag | Fluessiges konservierungsmittel |
ES2061890T5 (es) * | 1989-11-10 | 2002-04-16 | Thor Gmbh | Soluciones acuosas estabilizadas de 3-isotiazolinonas. |
WO1991007090A1 (de) * | 1989-11-16 | 1991-05-30 | Henkel Kommanditgesellschaft Auf Aktien | Bekämpfung von schleimbildenden mikroorganismen |
US5424324A (en) * | 1989-11-17 | 1995-06-13 | Rohm And Haas Company | Use of carbonyl stabilizers for 3-isothiazolones |
JPH05124917A (ja) | 1991-02-27 | 1993-05-21 | Rohm & Haas Co | イソチアゾロンの防護方法 |
US5217711A (en) * | 1991-10-16 | 1993-06-08 | Mariana De Oliveira | Hair care system |
EP0542489A3 (en) | 1991-11-14 | 1993-08-04 | Rohm And Haas Company | Microbicidal compositions comprising 3-isothiazolones and polycations |
US5342836A (en) | 1992-08-11 | 1994-08-30 | Rohm And Haas Company | Nitrogen-based stabilizers for 3-isothiazolones |
JPH08214775A (ja) * | 1995-02-16 | 1996-08-27 | Meiji Milk Prod Co Ltd | アミノ酸組成を人乳に類似させた育児用乳製品 |
DE19548710A1 (de) * | 1995-12-23 | 1997-06-26 | Riedel De Haen Ag | Konservierungsmittel, enthaltend Isothiazolinon-Derivate und Komplexbildner |
JP3198075B2 (ja) | 1997-06-09 | 2001-08-13 | 三菱レイヨン株式会社 | 多層構造アクリル重合体、およびそれを用いたメタクリル樹脂組成物 |
ATE302835T1 (de) * | 1997-06-09 | 2005-09-15 | Procter & Gamble | Zusammensetzung mit unkomplexiertem cyclodextrin zur geruchs- und knitterkontrolle |
JPH11180806A (ja) * | 1997-12-22 | 1999-07-06 | Kurita Water Ind Ltd | 抗菌性組成物 |
-
1999
- 1999-08-17 JP JP23087699A patent/JP3722268B2/ja not_active Expired - Lifetime
- 1999-08-31 EP EP99940595A patent/EP1110455B1/en not_active Expired - Lifetime
- 1999-08-31 ID IDW20010542A patent/ID28716A/id unknown
- 1999-08-31 DE DE69908954T patent/DE69908954T2/de not_active Expired - Fee Related
- 1999-08-31 BR BR9913385-7A patent/BR9913385A/pt not_active IP Right Cessation
- 1999-08-31 WO PCT/JP1999/004727 patent/WO2000013510A1/ja active IP Right Grant
- 1999-08-31 US US09/786,291 patent/US6429220B1/en not_active Expired - Fee Related
- 1999-08-31 ES ES99940595T patent/ES2203167T3/es not_active Expired - Lifetime
- 1999-08-31 CN CNB998106003A patent/CN1163137C/zh not_active Expired - Fee Related
- 1999-08-31 KR KR10-2001-7002818A patent/KR100413845B1/ko not_active IP Right Cessation
- 1999-08-31 AT AT99940595T patent/ATE242969T1/de not_active IP Right Cessation
- 1999-09-02 TW TW088115105A patent/TW486362B/zh not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5287230A (en) * | 1976-01-12 | 1977-07-20 | Kao Corp | Antimicrobial composition |
JPS62252708A (ja) * | 1986-03-04 | 1987-11-04 | サツトン・ラボラトリ−ズ・インコ−ポレ−テツド | 微生物増殖抑制組成物 |
JPH03178969A (ja) * | 1989-10-24 | 1991-08-02 | Rohm & Haas Co | 安定化した金属塩/3―イソチアゾロンの組成物 |
JPH09263504A (ja) * | 1995-12-19 | 1997-10-07 | Takeda Chem Ind Ltd | イソチアゾロン系化合物含有組成物及びイソチアゾロン系化合物の安定化法 |
Non-Patent Citations (2)
Title |
---|
COLLIER P.J. ET AL.: "Growth inhibitory and biocidal activity of some isothiazolone biocides", JOURNAL OF APPLIED BACTERIOLOGY,, vol. 69, no. 4, 1990, pages 569 - 577, XP002925577 * |
REHN D. ET AL.: "Marginalien zum Thema Konservierungi", JOURNAL OF THE SOCIETY OF COSMETIC CHEMISTS, vol. 31, no. 5, September 1980 (1980-09-01) - October 1980 (1980-10-01), pages 253 - 267, XP002925576 * |
Also Published As
Publication number | Publication date |
---|---|
JP3722268B2 (ja) | 2005-11-30 |
KR20010074950A (ko) | 2001-08-09 |
CN1316879A (zh) | 2001-10-10 |
ID28716A (id) | 2001-06-28 |
CN1163137C (zh) | 2004-08-25 |
KR100413845B1 (ko) | 2004-01-03 |
ATE242969T1 (de) | 2003-07-15 |
DE69908954T2 (de) | 2003-12-04 |
DE69908954D1 (de) | 2003-07-24 |
US6429220B1 (en) | 2002-08-06 |
BR9913385A (pt) | 2001-05-22 |
EP1110455B1 (en) | 2003-06-18 |
ES2203167T3 (es) | 2004-04-01 |
EP1110455A1 (en) | 2001-06-27 |
EP1110455A4 (en) | 2001-10-17 |
TW486362B (en) | 2002-05-11 |
JP2000143413A (ja) | 2000-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000013510A1 (fr) | Compositions antibacteriennes | |
KR970704348A (ko) | 2-이미다졸린-5-온을 함유하는 살진균성 조성물(fungicidal composition includind a 2-imidazoline-5-one) | |
EP1382248B1 (en) | Stabilized haloalkynyl microbicide compositions | |
ATE278321T1 (de) | Mikrobizide zusammensetzungen und verfahren, die mischungen von propiconazole und n-alkyl heterocylen sowie deren salze verwendet | |
RU94040905A (ru) | Фунгицидное средство на основе производных азола и способ торможения кристаллизации производных азола из водного препарата для опрыскивания | |
JP3692835B2 (ja) | 抗菌剤組成物 | |
JP2022012576A (ja) | 水処理剤および水処理剤の安定化方法 | |
JP2001089306A (ja) | 殺生物組成物 | |
TW314448B (ja) | ||
EP1012134B1 (en) | Quaternary ammonium phosphate compounds and method of preparing the same | |
JP3814085B2 (ja) | 藻類防除剤及び藻類防除方法 | |
CA1085828A (en) | Amphotericin b methyl ester salts | |
US5869510A (en) | Iron stabilizers for 3-isothiazolones | |
MXPA01002295A (en) | Antibacterial compositions | |
JP4621401B2 (ja) | 安定化されたイソチアゾロン組成物およびイソチアゾロンの安定化方法 | |
US5512213A (en) | Aqueous stabilized isothiazolone blends | |
JP2000128716A (ja) | 抗菌性組成物 | |
JP2002363016A (ja) | 微生物コントロール剤 | |
JP2016210739A (ja) | 水処理剤及び水処理方法 | |
JP3126613B2 (ja) | 工業用殺菌・静菌剤及び工業的殺菌・静菌方法 | |
CA2064088A1 (en) | Bivalent iron compounds | |
JP3311095B2 (ja) | 印刷版用湿し水 | |
JP3558368B2 (ja) | 3−イソチアゾロンおよび安定剤を含有する水性組成物 | |
JP3355562B2 (ja) | 工業用殺菌・静菌剤及び工業的殺菌・静菌方法 | |
JP2003104805A (ja) | 液状のハロゲン化ヒダントイン系殺微生物剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99810600.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CN ID KR MX SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09786291 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/002295 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017002818 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999940595 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999940595 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017002818 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999940595 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017002818 Country of ref document: KR |